Day: September 6, 2022

Eiger BioPharmaceuticals Provides Update on Status of Planned Peginterferon Lambda COVID-19 Emergency Use Authorization Application

PALO ALTO, Calif., Sept. 6, 2022 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. ( Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today provided an update on the status of its planned request for emergency […]